Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement
David Thomson(The Christie NHS Foundation Trust), Sue S. Yom(University of California, San Francisco), Pierre Blanchard(Inserm), Shlomo A. Koyfman(Cleveland Clinic), Quynh‐Thu Le(Stanford Medicine), Paul M. Harari(University of Wisconsin–Madison), Yoke Lim Soong(National Cancer Centre Singapore), J. Giralt(Vall d'Hebron Hospital Universitari), June Corry(St Vincent's Hospital Melbourne), Matthias Gückenberger(University of Zurich), John Waldron(Princess Margaret Cancer Centre), Ying J. Hitchcock(University of Utah), David M. Brizel(Duke Cancer Institute), Nancy Y. Lee(Memorial Sloan Kettering Cancer Center), Jonathan J. Beitler(Emory University), Renzo Corvò(Ospedale Policlinico San Martino), Panagiotis Balermpas(Goethe University Frankfurt), Adam S. Garden(The University of Texas MD Anderson Cancer Center), Jimmy J. Caudell(Moffitt Cancer Center), Juliette Thariat, Kevin J. Harrington(Royal Marsden NHS Foundation Trust), Danielle N. Margalit(Harvard University), Ying Sun(Qilu Hospital of Shandong University), Michelle Mierzwa(University of Michigan), David A. Palma(Western University), Jørgen Johansen(Odense University Hospital), Mererid Evans, Vincent Grégoire(Centre Léon Bérard), W. Budach(Heinrich Heine University Düsseldorf), Johannes A. Langendijk(University of Groningen), J.H.A.M. Kaanders(Radboud University Medical Center), Sandro Porceddu(The University of Queensland)
International Journal of Radiation Oncology*Biology*Physics
April 14, 2020
Cited by 211
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2004|3.2k
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
|The Lancet|2019|1.9k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k